Viridian Therapeutics, Inc. Profile Avatar - Palmy Investing

Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye…

Biotechnology
US, Waltham [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Viridian Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of VRDN's Analysis
CIK: 1590750 CUSIP: 92790C104 ISIN: US92790C1045 LEI: - UEI: -
Secondary Listings
VRDN has no secondary listings inside our databases.